IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v26y2008i1p17-32.html
   My bibliography  Save this article

Cost-Effectiveness Analyses of Hepatitis A Vaccine

Author

Listed:
  • Andrea Anonychuk
  • Andrea Tricco
  • Chris Bauch
  • Ba’ Pham
  • Vladimir Gilca
  • Bernard Duval
  • Ava John-Baptiste
  • Gloria Woo
  • Murray Krahn

Abstract

Cost-effectiveness/cost-utility studies of hepatitis A vaccine were identified via a series of literature searches (MEDLINE, EMBASE, HSTAR and SSCI). Citations and full-text articles were reviewed independently by two reviewers. Reference searching, author searches and expert consultation ensured literature saturation. Incremental cost-effectiveness ratios (ICERs) were abstracted for base-case analyses, converted to $US, year 2005 values, and categorised to reflect various levels of cost effectiveness. Quality of reporting, methodological issues and key modelling issues were assessed using frameworks published in the literature. Thirty-one cost-effectiveness studies (including 12 cost-utility analyses) were included from full-text article review (n=58) and citation screening (n=570). These studies evaluated universal mass vaccination (n=14), targeted vaccination (n=17) and vaccination of susceptibles (i.e. individuals initially screened for antibody and, if susceptible, vaccinated) [n=13]. For universal vaccination, 50% of the ICERs were >$US20 000 per QALY or life-year gained. Analyses evaluating vaccination in children, particularly in high incidence areas, produced the most attractive ICERs. For targeted vaccination, cost effectiveness was highly dependent on the risk of infection. Incidence, vaccine cost and discount rate were the most influential parameters in sensitivity analyses. Overall, analyses that evaluated the combined hepatitis A/hepatitis B vaccine, adjusted incidence for under-reporting, included societal costs and that came from studies of higher methodological quality tended to have more attractive cost-effectiveness ratios. Methodological quality varied across studies. Major methodological flaws included inappropriate model type, comparator, incidence estimate and inclusion/exclusion of costs. Copyright Adis Data Information BV 2008

Suggested Citation

  • Andrea Anonychuk & Andrea Tricco & Chris Bauch & Ba’ Pham & Vladimir Gilca & Bernard Duval & Ava John-Baptiste & Gloria Woo & Murray Krahn, 2008. "Cost-Effectiveness Analyses of Hepatitis A Vaccine," PharmacoEconomics, Springer, vol. 26(1), pages 17-32, January.
    • Handle: RePEc:spr:pharme:v:26:y:2008:i:1:p:17-32
    DOI: 10.2165/00019053-200826010-00003
    as

    Download full text from publisher

    File URL: http://hdl.handle.net/10.2165/00019053-200826010-00003
    Download Restriction: Access to full text is restricted to subscribers.
    File URL: https://libkey.io/10.2165/00019053-200826010-00003?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Mason, James & Eccles, Martin & Freemantle, Nick & Drummond, Michael, 1999. "A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines," Health Policy, Elsevier, vol. 47(1), pages 37-52, April.
    2. Davies, Linda & Coyle, Douglas & Drummond, Michael & The EC Network on the Methodology of Economic Appraisal of Health Technology, 1994. "Current status of economic appraisal of health technology in the European community: Report of the network," Social Science & Medicine, Elsevier, vol. 38(12), pages 1601-1607, June.
    3. Drummond, Michael & Cooke, Jonathan & Walley, Tom, 1997. "Economic evaluation under managed competition: Evidence from the U.K," Social Science & Medicine, Elsevier, vol. 45(4), pages 583-595, August.
    4. M. Brisson & W. J. Edmunds, 2003. "Economic Evaluation of Vaccination Programs: The Impact of Herd-Immunity," Medical Decision Making, , vol. 23(1), pages 76-82, January.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Kristen Scheckelhoff & Ayesha Ejaz & Igor V. Erovenko & Jan Rychtář & Dewey Taylor, 2021. "Optimal Voluntary Vaccination of Adults and Adolescents Can Help Eradicate Hepatitis B in China," Games, MDPI, vol. 12(4), pages 1-13, October.
    2. Maria-Florencia Hutter & Roberto Rodríguez-Ibeas & Fernando Antonanzas, 2014. "Methodological reviews of economic evaluations in health care: what do they target?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(8), pages 829-840, November.
    3. van Ackere, Ann & Schulz, Peter J., 2020. "Explaining vaccination decisions: A system dynamics model of the interaction between epidemiological and behavioural factors," Socio-Economic Planning Sciences, Elsevier, vol. 71(C).
    4. Anna K. Lugnér & Sido D. Mylius & Jacco Wallinga, 2010. "Dynamic versus static models in cost‐effectiveness analyses of anti‐viral drug therapy to mitigate an influenza pandemic," Health Economics, John Wiley & Sons, Ltd., vol. 19(5), pages 518-531, May.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Hoffmann, Christiane AU -, 2000. "The influence of economic evaluation studies on decision making.: A European survey," Health Policy, Elsevier, vol. 52(3), pages 179-192, July.
    2. James Mason & Martin Eccles & Nick Freemantle & Mike Drummond, 1998. "NICEly does it: economic analysis within evidence-based clinical practice guidelines," Working Papers 164chedp, Centre for Health Economics, University of York.
    3. Eddama, Oya & Coast, Joanna, 2008. "A systematic review of the use of economic evaluation in local decision-making," Health Policy, Elsevier, vol. 86(2-3), pages 129-141, May.
    4. Mason, James & Eccles, Martin & Freemantle, Nick & Drummond, Michael, 1999. "A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines," Health Policy, Elsevier, vol. 47(1), pages 37-52, April.
    5. Gregory Merlo & Katie Page & Pauline Zardo & Nicholas Graves, 2019. "Applying an Implementation Framework to the Use of Evidence from Economic Evaluations in Making Healthcare Decisions," Applied Health Economics and Health Policy, Springer, vol. 17(4), pages 533-543, August.
    6. Caroline L. Trotter & W. John Edmunds, 2006. "Reassessing the Cost-Effectiveness of Meningococcal Serogroup C Conjugate (MCC) Vaccines Using a Transmission Dynamic Model," Medical Decision Making, , vol. 26(1), pages 38-47, January.
    7. Banta, David, 2003. "The development of health technology assessment," Health Policy, Elsevier, vol. 63(2), pages 121-132, February.
    8. Anna García‐Altés, 2001. "Twenty years of health care economic analysis in Spain: are we doing well?," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 715-729, December.
    9. W. Dominika Wranik & Liesl Gambold & Natasha Hanson & Adrian Levy, 2017. "The evolution of the cancer formulary review in Canada: Can centralization improve the use of economic evaluation?," International Journal of Health Planning and Management, Wiley Blackwell, vol. 32(2), pages 232-260, April.
    10. Wang, Jianwei & Xu, Wenshu & Chen, Wei & Yu, Fengyuan & He, Jialu, 2021. "Information sharing can suppress the spread of epidemics: Voluntary vaccination game on two-layer networks," Physica A: Statistical Mechanics and its Applications, Elsevier, vol. 583(C).
    11. Perleth, Matthias & Jakubowski, Elke & Busse, Reinhard, 2001. "What is `best practice' in health care? State of the art and perspectives in improving the effectiveness and efficiency of the European health care systems," Health Policy, Elsevier, vol. 56(3), pages 235-250, June.
    12. Arnold Kamis & Yuji Zhang & Tamara Kamis, 2017. "A Multiyear Model of Influenza Vaccination in the United States," IJERPH, MDPI, vol. 14(8), pages 1-14, July.
    13. Legood, Rosa & Wolstenholme, Jane & Gray, Alastair, 2009. "From cost-effectiveness information to decision-making on liquid-based cytology: Mind the gap," Health Policy, Elsevier, vol. 89(2), pages 193-200, February.
    14. Lessard, Chantale, 2007. "Complexity and reflexivity: Two important issues for economic evaluation in health care," Social Science & Medicine, Elsevier, vol. 64(8), pages 1754-1765, April.
    15. Mike Drummond & Jonathan Cooke & Tom Walley, 1996. "Economic evaluation in health care decision making: evidence from the UK," Working Papers 148chedp, Centre for Health Economics, University of York.
    16. van Os, Nicole & Niessen, Louis W. & Bilo, Henk J. G. & Casparie, Anton F. & van Hout, Ben A., 2000. "Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines," Health Policy, Elsevier, vol. 51(3), pages 135-147, April.
    17. Andrew M. Jones (ed.), 2012. "The Elgar Companion to Health Economics, Second Edition," Books, Edward Elgar Publishing, number 14021.
    18. Don Kenkel, 2006. "WTP- and QALY-Based Approaches to Valuing Health for Policy: Common Ground and Disputed Territory," Environmental & Resource Economics, Springer;European Association of Environmental and Resource Economists, vol. 34(3), pages 419-437, July.
    19. Anna K. Lugnér & Sido D. Mylius & Jacco Wallinga, 2010. "Dynamic versus static models in cost‐effectiveness analyses of anti‐viral drug therapy to mitigate an influenza pandemic," Health Economics, John Wiley & Sons, Ltd., vol. 19(5), pages 518-531, May.
    20. Jansson, Sandra & Anell, Anders, 2006. "The impact of decentralised drug-budgets in Sweden - a survey of physicians' attitudes towards costs and cost-effectiveness," Health Policy, Elsevier, vol. 76(3), pages 299-311, May.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:26:y:2008:i:1:p:17-32. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.